Mascola JR - Search Results

1

Mascola JR, McNeil JG, Birx DL. Mascola JR, et al. Nat Med. 1998 Jul;4(7):746. doi: 10.1038/nm0798-746a. Nat Med. 1998. PMID: 9662343 No abstract available.

2

Human immunodeficiency virus type 1 candidate vaccine breakthrough infection.

Mascola JR, McNeil JG. Mascola JR, et al. J Infect Dis. 1995 Dec;172(6):1636-8. doi: 10.1093/infdis/172.6.1636. J Infect Dis. 1995. PMID: 7594736 No abstract available.

3

AIDS vaccines. Are we ready for human efficacy trials?

Mascola JR, McNeil JG, Burke DS. Mascola JR, et al. JAMA. 1994 Aug 10;272(6):488-9. doi: 10.1001/jama.272.6.488. JAMA. 1994. PMID: 8040986 No abstract available.

4

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS. Mascola JR, et al. J Infect Dis. 1994 Jan;169(1):48-54. doi: 10.1093/infdis/169.1.48. J Infect Dis. 1994. PMID: 8277197

5

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. Mascola JR, et al. J Infect Dis. 1996 Feb;173(2):340-8. doi: 10.1093/infdis/173.2.340. J Infect Dis. 1996. PMID: 8568294 Clinical Trial.

6

Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa.

McCutchan FE, Artenstein AW, Sanders-Buell E, Salminen MO, Carr JK, Mascola JR, Yu XF, Nelson KE, Khamboonruang C, Schmitt D, Kieny MP, McNeil JG, Burke DS. McCutchan FE, et al. Among authors: mascola jr. J Virol. 1996 Jun;70(6):3331-8. doi: 10.1128/JVI.70.6.3331-3338.1996. J Virol. 1996. PMID: 8648662 Free PMC article.

7

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.

Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS. Mascola JR, et al. AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1319-28. doi: 10.1089/aid.1996.12.1319. AIDS Res Hum Retroviruses. 1996. PMID: 8891111

8

The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.

Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW. Michael NL, et al. Among authors: mascola jr. Nat Med. 1997 Mar;3(3):338-40. doi: 10.1038/nm0397-338. Nat Med. 1997. PMID: 9055864

9

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, Birx DL. VanCott TC, et al. Among authors: mascola jr. J Virol. 1997 Jun;71(6):4319-30. doi: 10.1128/JVI.71.6.4319-4330.1997. J Virol. 1997. PMID: 9151820 Free PMC article.

10

Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts.

Michael NL, Brown AE, Voigt RF, Frankel SS, Mascola JR, Brothers KS, Louder M, Birx DL, Cassol SA. Michael NL, et al. Among authors: mascola jr. J Infect Dis. 1997 Jun;175(6):1352-9. doi: 10.1086/516467. J Infect Dis. 1997. PMID: 9180174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

630 results

Search Page

Filters